SCD and hepatocellular carcinoma: Sorafenib disrupts monounsaturated fatty acid synthesis mediated by stearoyl-CoA desaturase-1 (SCD1) through the ATP-AMPK-mTOR-SREBP1 signaling pathway, leading to HCC cell death (49).